



27 September 2022

Incanthera plc

("Incanthera" or the "Company")

Result of AGM 2022

Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed.

The Company would like to thank all Shareholders who returned their Proxy form and attended in person.

The company wishes all Shareholders and their families well.

For further enquiries:

Incanthera plc

www.incanthera.com

Tim McCarthy, Chairman

tim.mccarthy@incanthera.com

+44 (0) 7831 675747

Simon Ward, Chief Executive Officer

simon.ward@incanthera.com

+44 (0) 7747 625506

Suzanne Brocks, Head of Communications

suzanne.brocks@incanthera.com

+44 (0) 7776 234600

Aquis Exchange Corporate Adviser:

Cairn Financial Advisers LLP

Jo Turner/James Lewis

+44 (0) 20 7213 0880

Broker:

Stanford Capital Partners Ltd

Patrick Claridge/John Howes/Bob Pountney

+44 (0) 20 3815 8880

Notes to Editors

Incanthera is a specialist oncology company focused on innovative technologies in oncology and dermatology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.

The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.

Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: www.incanthera.com

[@incantherapl](#)